Japan Tissue Engineering Co., Ltd.

With the acquisition of the NGB (Next-Generation Bioprinting) high-resolution robotic bioprinting platform developed by Poietis the University of Barcelona becomes a reference in Tissue Engineering Poietis will also support CREATIO team in the creation of tissues and organs, process development and validation Barcelona, Spain and Pessac, France – September 26, 2022 - Poietis, a healthtech pioneer company in bioprinting, announced today the partnership with CREATIO, the Production and Validation Center for Advanced Therapies for the manufacture of Advanced Therapy Medicinal Product (ATMP) of the University of Barcelona (UB) to install its NGB-C bioprinting platform in their cGMP facilities. Bioprinting consists on the making of human artificial tissues through the combination of bio-materials and cells. This technology, which is part of the tissue engineering has brought a revolution in the pharmaceutical sector, with the creation of three-dimensional cellular models, and in the biomedical sector, focused on the generation of tissues and organs, for direct clinical applications. Despite high clinical and commercial expectations, Tissue Engineering (TE) continues to face major challenges that impede the large-scale adoption of TE products in the market: - the availability of automated manufacturing technologies, - complex logistics requiring a high level of coordination- the ability to offer patient-specific treatments (e.g. by integrating patient cells or anatomical information), - cost-effectiveness and cost-benefit ratio with respect to existing therapies (drugs and medical devices) to support affordability and reimbursement. As a result, only a small number of TE products have obtained marketing authorization. Thanks to its strong expertise in bioprinting and a proximity to physicians and cell biologists, Poietis specifically designed the Next-Generation Bioprinting (NGB) platform. The NGB-C platform is a unique solution to unmet needs that provides clinicians and patients with automated equipment that enables: - manufacture patient-specific tissues (taking into account biological complexity and custom design), - standardize the tissue manufacturing process (thus ensuring comparability and reproducibility of the process), - improve access to treatment (by robotising and enabling point-of-care manufacturing). The NGB platform addresses critical limitations of existing tissue engineering methods and differentiates itself from current competing 3D bioprinting technologies through the use of high-resolution laser-assisted bioprinting. High-resolution bioprinting could be considered the next standard in tissue manufacturing, as it allows control of the internal tissue architecture and cellular microenvironment at the cellular scale with high cell viability, unlike other bioprinting technologies. NGB leads to a paradigm shift, in which bioprinting becomes cytocentric, no longer conditioned by the printing device (e.g. nozzle diameter), but driven by the laws of biology. This installation comes after our first NGB platform installed at the Hospital of Marseille to prepare bioprinted skin clinical trials. The market of advanced therapies in Spain is one of the top ones in the world with a great development in cell therapy and gene therapy. CREATIO, located at the Faculty of Medicine and Health Sciences of the University of Barcelona, has become a leading center in Europe for its production of cell and gene therapies for different therapeutic applications. However, the lack of facilities to produce tissues for regenerative medicine is slowing the most ambitious developments. Therefore, NGB-C bioprinting platform will allow CREATIO, and the UB to be in the leading positions of regenerative medicine worldwide. CREATIO intends to use the NGB bioprinting platform in various collaborations in basic and translational research as well as production of ATMPs for other hospitals in Spain. The director of Creatio, Dr. Josep M. Canals, describes the acquisition of this bioprinter as an “important strategical step”. “Regenerative medicine and tissue engineering are providing great advances for producing tissues and organs in the laboratory, but we need one more step in the clinic so that these can be transplanted in humans. The new bioprinter in the CREATIO facilities will allow us to advance in the application of regenerative medicine for many diseases that go from skin regeneration to the nervous system regeneration strategies”. Moreover, the rector of the University of Barcelona, Joan Guàrdia, congratulated the UB for its leading position in innovation in the field of health: “Innovation is part of the University of Barcelona’s DNA. This milestone is important for placing the UB at the front of tissue regenerative medicine, since there is only one bioprinter with such features in the world”. With this acquisition, the University of Barcelona will contribute to the definite clinical application of artificial production of tissues and organs, providing direct benefits to Society. "The installation of NGB-C bioprinting platform in a center such as CREATIO at UB is an important milestone for Poietis and is in line with our vision to bring a 3D bioprinter in every hospital! That is a closer step to bring bioprinting technology for the patients", says Fabien Guillemot, President and Founder of Poietis. Bruno Brisson, Co-founder and Business Development Director at Poietis concluded: "We are delighted to partner with UB and CREATIO to establish this bioprinting facility at the foerefront of innovation. We will be supporting CREATIO team in process development and validation as well and that opens up new opportunities and case studies for new clinical applications for bioprinting This partnership is also a concrete step of the market adoption of our offer in order to to expand capabilities of Cell & Gene Therapy Centers to bioprinting and enable them to produce implantable Tissue Engineered products". More information on the project:

Increase in prevalence of eye diseases such as dry eye syndrome and allergic conjunctivitis drives the growth of the global OTC artificial tears market, Increase in prevalence of eye diseases such as dry eye syndrome and allergic conjunctivitis, rise in demand for artificial tears products, and surge in investment in R&D activities by various healthcare companies drive the growth of the global OTC artificial tears market. The supply chain disrupted due to lockdown imposed by governments of various countries. This led to shortage of some medical products for distribution. Global OTC Artificial Tears Market garnered $4.37 billion in 2020, and is estimated to reach $6.39 billion by 2028, witnessing a CAGR of 4.9% from 2021 to 2028. The report offers an extensive analysis of changing market trends, top segments, major investment pockets, regional scenarios, value chain, and competitive landscape. Request Sample Report at: Covid-19 Scenario:- The supply chain disrupted due to lockdown imposed by governments of various countries. This led to shortage of some medical products for distribution. However, governments provided relaxation for medical products during the pandemic, which in turn, is expected to improve the prospects of the market. The availability of over the counter (OTC) products such as artificial tears further helped in speedy expansion. In addition, the online pharmacies further catered to the demand during the pandemic. The report offers detailed segmentation of the global OTC artificial tears market based on product type, container type, formulation, application, distribution channel, and region. Based on product type, the solution segment held the highest market share, accounting for around two-fifths of the total share in 2020, and is projected to maintain its lead position during the forecast period. However, the gel segment is estimated to register the highest CAGR of 5.4% from 2021 to 2028. Based on container type, the plastic multi-dose container segment accounted for the largest market share in 2020, contributing to more than two-fifths of the global OTC artificial tears market, and is estimated to continue its leadership status during the forecast period. Moreover, this segment is projected to witness the largest CAGR of 5.2% from 2021 to 2028. Based on region, North America contributed to the largest market share in 2019, holding more than one-third of the total share, and is expected to maintain its dominant share in terms of revenue by 2028. However, Asia-Pacific is estimated to portray the highest CAGR of 6.0% during the forecast period. Leading Market Players:- AbbVie, Inc., Alcon, Akorn, Inc., Johnson & Johnson, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Ocusoft, Sun Pharmaceutical Industries Limited, Similasan Corporation, Ursapharm Arzneimittel GmbH. Similar Reports: Blood Culture Test market - Global Opportunity Analysis and Industry Forecast, 2019-2028 Tissue Engineering Market - Global Opportunity Analysis and Industry Forecast, 2019-2028 About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tissue Engineering Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Tissue Engineering Market to Reach $26.8 Billion by 2027 - Amid the COVID-19 crisis, the global market for Tissue Engineering estimated at US$11 Billion in the year 2020, is projected to reach a revised size of US$26.8 Billion by 2027, growing at a CAGR of 13.5% over the analysis period 2020-2027. Orthopedics, Musculoskeletal & Spine, one of the segments analyzed in the report, is projected to record a 12.1% CAGR and reach US$6.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiology & Vascular segment is readjusted to a revised 15.7% CAGR for the next 7-year period. - The U.S. Market is Estimated at $3.3 Billion, While China is Forecast to Grow at 13.1% CAGR - The Tissue Engineering market in the U.S. is estimated at US$3.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2027 trailing a CAGR of 13.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.7% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR. - Cord Blood & Cell Banking Segment to Record 14.7% CAGR - In the global Cord Blood & Cell Banking segment, USA, Canada, Japan, China and Europe will drive the 14.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.2 Billion by the year 2027. Select Competitors (Total 33 Featured) - Acelity L.P. Inc. Advanced Cell Technology Allergan Plc Arteriocyte Athersys Baxter International Inc BioMimetic Therapeutics Cook Biotech Inc. CryoLife DePuy Synthes (Johnson & Johnson Services, Inc.) Integra Life Sciences Corporation LifeCell Kinetic Concepts Medtronic Organogenesis Inc. RTI surgical Sanofi StemCells, Inc. Stryker Corporation Zimmer Biomet Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Tissue Engineering Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World 7-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 Table 3: World Current & Future Analysis for Orthopedics, Musculoskeletal & Spine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 4: World 7-Year Perspective for Orthopedics, Musculoskeletal & Spine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 5: World Current & Future Analysis for Cardiology & Vascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 6: World 7-Year Perspective for Cardiology & Vascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 7: World Current & Future Analysis for Cord Blood & Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World 7-Year Perspective for Cord Blood & Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 9: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 10: World 7-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 11: World Current & Future Analysis for Gastrointestinal & Gynecology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 12: World 7-Year Perspective for Gastrointestinal & Gynecology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 15: USA Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 16: USA 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 CANADA Table 17: Canada Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 18: Canada 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 JAPAN Table 19: Japan Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 20: Japan 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 CHINA Table 21: China Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 22: China 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 23: Europe Current & Future Analysis for Tissue Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 24: Europe 7-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 Table 25: Europe Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: Europe 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 FRANCE Table 27: France Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 28: France 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 GERMANY Table 29: Germany Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 30: Germany 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 ITALY Table 31: Italy Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Italy 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 UNITED KINGDOM Table 33: UK Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 34: UK 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 REST OF EUROPE Table 35: Rest of Europe Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 36: Rest of Europe 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 ASIA-PACIFIC Table 37: Asia-Pacific Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Asia-Pacific 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 REST OF WORLD Table 39: Rest of World Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 40: Rest of World 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 IV. COMPETITION Total Companies Profiled: 33 Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001